Form 4: IOVANCE Biotherapeutics Director Athena Countouriotis Receives Significant Equity Grant

IOVANCE Biotherapeutics, Inc. Director Athena Countouriotis was granted 67,546 deferred restricted stock units (DRSUs) as part of her compensation, aligning her interests with shareholders.

Summary

• Athena Countouriotis, a Director of IOVANCE Biotherapeutics, Inc. (IOVA), was granted 67,546 Deferred Restricted Stock Units (DRSUs) on June 13, 2025.
• These DRSUs represent a contingent right to receive one share of the Issuer's common stock each.
• The grant was made pursuant to the Issuer's 2018 Equity Incentive Plan (as amended).
• The DRSUs vest on the earlier of the first anniversary of the transaction date (June 13, 2026) or the day prior to the Issuer's next annual shareholder meeting, provided Ms. Countouriotis continues to provide service.
• Issuance of the common stock will be deferred until the earlier of three months after her resignation/removal/death/disability, a change in control, or ten years from the transaction date (June 13, 2035).

Sentiment

Score: 6

Explanation: The document reports a standard, expected equity grant to a director, which is a neutral to slightly positive event as it aligns interests. There are no negative surprises or significant positive catalysts.

Positives

• The grant of 67,546 DRSUs to Director Athena Countouriotis aligns her long-term interests with those of the company's shareholders.
• This equity-based compensation serves as a retention mechanism for key board members.
• The grant is part of a pre-existing, approved equity incentive plan (2018 Equity Incentive Plan), indicating a structured approach to compensation.

Negatives

• The DRSUs have no immediate cash value upon grant, as the common stock issuance is deferred.
• Vesting is contingent on continued service, meaning the director must remain with the company to realize the value.
• The ultimate value of the grant is dependent on the future market price of IOVANCE common stock, introducing market risk.

Risks

• Service Contingency Risk: The DRSUs will only vest if Athena Countouriotis continues to provide service to the Issuer until the vesting date.
• Market Price Risk: The value of the common stock received upon issuance will fluctuate with IOVANCE's share price, potentially resulting in a lower value than anticipated.
• Dilution Risk: While not immediate, the eventual issuance of 67,546 shares of common stock could lead to minor dilution for existing shareholders.

Future Outlook

The document indicates that the 67,546 DRSUs granted to Director Athena Countouriotis are expected to vest on the earlier of June 13, 2026, or the day prior to the company's next annual shareholder meeting, contingent on her continued service. The actual issuance of common stock will be deferred until a later event, such as her departure from the board, a change in control, or up to ten years from the grant date.

Industry Context

Equity grants, such as Deferred Restricted Stock Units (DRSUs), are a common form of compensation for directors and executives in the biotechnology and pharmaceutical industries. This practice is designed to align the interests of board members with those of shareholders by tying a portion of their compensation to the company's long-term stock performance. IOVANCE Biotherapeutics' use of DRSUs is consistent with standard compensation practices aimed at attracting and retaining experienced leadership in a competitive sector.

Comparison to Industry Standards

• It is difficult to provide specific comparable companies, projects, or results based solely on this Form 4 filing, as it details a single director's equity grant without broader compensation plan details or industry benchmarks.
• However, the grant of equity to directors is a standard practice across the biotech industry, including companies like Gilead Sciences, Amgen, and Regeneron Pharmaceuticals, which frequently use stock options, restricted stock units (RSUs), or similar equity instruments as part of their non-employee director compensation packages to incentivize long-term value creation and retention.
• The specific number of units granted would typically be benchmarked against peer group compensation data, which is not available in this document.

Corporate Governance

Related Party Transactions

• The grant of 67,546 Deferred Restricted Stock Units (DRSUs) to Athena Countouriotis, a Director of IOVANCE Biotherapeutics, Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board of directors. This is a standard and disclosed form of related party compensation.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial interests with long-term shareholder value creation. The eventual issuance of shares could result in minor dilution.
• Employees: No direct impact on general employees mentioned.
• Customers: No direct impact on customers mentioned.
• Suppliers: No direct impact on suppliers mentioned.
• Creditors: No direct impact on creditors mentioned.

Next Steps

• Continued service of Athena Countouriotis to IOVANCE Biotherapeutics.
• Vesting of the 67,546 DRSUs on or after June 13, 2026, contingent on continued service.
• Eventual issuance of common stock shares upon the occurrence of specified deferral events.

Key Dates

Keywords

IOVANCE Biotherapeutics, IOVA, SEC Form 4, insider transaction, equity grant, deferred restricted stock unit, DRSU, director compensation, Athena Countouriotis, corporate governance, executive compensation, biotech